Biotech Investors Stung By Drug Pricing Flap
August 29, 2016 at 05:22 AM EDT
Risk remains off until we can determine that the sentiment damage from drug pricing is not overdone. Remember we are still in a bear market with major stocks and ETFs down YTD.